Tags

Type your tag names separated by a space and hit enter

An open-label, randomized multicenter study comparing the efficacy and safety of Cyclo 3 Fort versus hydroxyethyl rutoside in chronic venous lymphatic insufficiency.
Angiology. 2000 Jul; 51(7):535-44.A

Abstract

The present study was designed to compare the safety and efficacy of a combination of Ruscus aculeatus, hesperidin methyl chalcone, and ascorbic acid (Cyclo 3 Fort) versus that of hydroxyethyl rutoside in treatment of chronic venous lymphatic insufficiency. This open-label, randomized multicenter study was conducted on outpatients treated for 90 days. The patients were from three different regions of Argentina. Eighty patients, men and women, 30 to 70 years of age, with symptoms of chronic venous lymphatic insufficiency, ie, heavy, tired, swollen, or painful legs, were enrolled and assigned to two groups: one group treated with Cyclo 3 Fort, the other with rutoside. The symptoms were assessed at baseline, and after 30, 60, and 90 days. The patient was asked to assess subjective symptoms, and the physician measured the size of the affected limbs. The efficacy was rated on a 3-point scale and safety was evaluated by the number of side effects. The results show that when all patients were comparable at baseline, after 90 days, patients treated with Cyclo 3 Fort reported more rapid and complete regression of symptoms than those in the rutoside group, a statistically significant difference (p < 0.01). Likewise, a significant reduction in affected limb size was observed in both groups but persisted after 90 days in the Cyclo 3 Fort group only (p < 0.01). Cyclo 3 Fort was safe and more effective than rutoside in the treatment of venous lymphatic insufficiency, and the Cyclo 3 Fort efficacy is probably associated with its unique mechanism of action.

Authors+Show Affiliations

Spanish Hospital of Buenos Aires, Argentina.No affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial

Language

eng

PubMed ID

10917578

Citation

Beltramino, R, et al. "An Open-label, Randomized Multicenter Study Comparing the Efficacy and Safety of Cyclo 3 Fort Versus Hydroxyethyl Rutoside in Chronic Venous Lymphatic Insufficiency." Angiology, vol. 51, no. 7, 2000, pp. 535-44.
Beltramino R, Penenory A, Buceta AM. An open-label, randomized multicenter study comparing the efficacy and safety of Cyclo 3 Fort versus hydroxyethyl rutoside in chronic venous lymphatic insufficiency. Angiology. 2000;51(7):535-44.
Beltramino, R., Penenory, A., & Buceta, A. M. (2000). An open-label, randomized multicenter study comparing the efficacy and safety of Cyclo 3 Fort versus hydroxyethyl rutoside in chronic venous lymphatic insufficiency. Angiology, 51(7), 535-44.
Beltramino R, Penenory A, Buceta AM. An Open-label, Randomized Multicenter Study Comparing the Efficacy and Safety of Cyclo 3 Fort Versus Hydroxyethyl Rutoside in Chronic Venous Lymphatic Insufficiency. Angiology. 2000;51(7):535-44. PubMed PMID: 10917578.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - An open-label, randomized multicenter study comparing the efficacy and safety of Cyclo 3 Fort versus hydroxyethyl rutoside in chronic venous lymphatic insufficiency. AU - Beltramino,R, AU - Penenory,A, AU - Buceta,A M, PY - 2000/8/5/pubmed PY - 2000/8/19/medline PY - 2000/8/5/entrez SP - 535 EP - 44 JF - Angiology JO - Angiology VL - 51 IS - 7 N2 - The present study was designed to compare the safety and efficacy of a combination of Ruscus aculeatus, hesperidin methyl chalcone, and ascorbic acid (Cyclo 3 Fort) versus that of hydroxyethyl rutoside in treatment of chronic venous lymphatic insufficiency. This open-label, randomized multicenter study was conducted on outpatients treated for 90 days. The patients were from three different regions of Argentina. Eighty patients, men and women, 30 to 70 years of age, with symptoms of chronic venous lymphatic insufficiency, ie, heavy, tired, swollen, or painful legs, were enrolled and assigned to two groups: one group treated with Cyclo 3 Fort, the other with rutoside. The symptoms were assessed at baseline, and after 30, 60, and 90 days. The patient was asked to assess subjective symptoms, and the physician measured the size of the affected limbs. The efficacy was rated on a 3-point scale and safety was evaluated by the number of side effects. The results show that when all patients were comparable at baseline, after 90 days, patients treated with Cyclo 3 Fort reported more rapid and complete regression of symptoms than those in the rutoside group, a statistically significant difference (p < 0.01). Likewise, a significant reduction in affected limb size was observed in both groups but persisted after 90 days in the Cyclo 3 Fort group only (p < 0.01). Cyclo 3 Fort was safe and more effective than rutoside in the treatment of venous lymphatic insufficiency, and the Cyclo 3 Fort efficacy is probably associated with its unique mechanism of action. SN - 0003-3197 UR - https://www.unboundmedicine.com/medline/citation/10917578/An_open_label_randomized_multicenter_study_comparing_the_efficacy_and_safety_of_Cyclo_3_Fort_versus_hydroxyethyl_rutoside_in_chronic_venous_lymphatic_insufficiency_ L2 - https://journals.sagepub.com/doi/10.1177/000331970005100702?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -